Status:
COMPLETED
Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure
Lead Sponsor:
Hôpital Louis Mourier
Conditions:
Respiratory Syndrome, Acute, Severe
Hypoxic Respiratory Failure
Eligibility:
All Genders
18+ years
Brief Summary
Nasal High Flow oxygen therapy (NHF) is commonly used as first line ventilatory support in patients with acute hypoxemic respiratory failure (AHRF). It's use has been initially limited in Covid-19 pat...
Detailed Description
Nasal High Flow oxygen therapy (NHF) is one of the newer methods of oxygenation commonly used in critical care during acute hypoxemic respiratory failure (AHRF). For various reasons (fear of a putativ...
Eligibility Criteria
Inclusion
- Covid-19 pneumonia
- acute hypoxemic respiratory failure
- need for nasal high flow therapy as first line therapy
- admission to intensive care
Exclusion
- intubation prior to NHF therapy
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 4 2020
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04385823
Start Date
March 1 2020
End Date
May 4 2020
Last Update
May 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Louis Mourier, Assistance Publique - Hôpitaux de Paris
Colombes, France, 92700